Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821780 | 0.93 | — | — | |
| SCHEMBL18028958 | 0.93 | — | — | |
| SCHEMBL18028988 | 0.93 | — | — | |
| SCHEMBL1919014 | 0.92 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12318703 | 0.92 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19833518 | 0.91 | — | — | |
| SCHEMBL17274526 | 0.91 | — | — | |
| SCHEMBL19821786 | 0.91 | — | — | |
| SCHEMBL19833543 | 0.90 | — | — | |
| SCHEMBL19821778 | 0.90 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| US-10570108-B2 | Substituted benzofuran compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180099953-A1 | BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180030019-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030017-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030056-A1 | BENZOFURANS SUBSTITUTED WITH BICYCLIC SECONDARY BENZAMIDE AS HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2017165233-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016133970-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133972-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133963-A1 | BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133961-A1 | BENZOFURANS SUBSTITUTED WITH BICYCLIC SECONDARY BENZAMIDE AS HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099953-A1 | BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS | EIF2AK2, UGT2B7, TMBIM6 | CYP3A4 107/4885CYP2C9 94/4885CYP2C19 86/4885 |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | CYP3A4 94/4885CYP2C9 175/4885CYP2C19 140/4885 |
| US-10570108-B2 | Substituted benzofuran compounds for the treatment of hepatitis C | GOT1, GOT2, HAVCR2 | CYP3A4 49/4885CYP2C9 120/4885CYP2C19 94/4885 |
| US-20180030019-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | GOT1, GOT2, HAVCR2 | CYP3A4 49/4885CYP2C9 120/4885CYP2C19 94/4885 |
| US-20180030056-A1 | BENZOFURANS SUBSTITUTED WITH BICYCLIC SECONDARY BENZAMIDE AS HCV INHIBITORS | ZC3HAV1, TMBIM6, UGT2B7 | CYP3A4 206/4885CYP2C9 204/4885CYP2C19 241/4885 |
| US-20180030017-A1 | BENZOFURANS SUBSTITUTED WITH PRIMARY BENZAMIDE AS HCV INHIBITORS | ZC3HAV1, TMBIM6, EIF2AK2 | CYP3A4 159/4885CYP2C9 172/4885CYP2C19 126/4885 |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | HAVCR2, UGT2B7, GOT1 | CYP3A4 94/4885CYP2C9 175/4885CYP2C19 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.